SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 8% Thursday after the company said its experimental drug amlitelimab met the main goals of a late-stage trial in atopic dermatitis but showed ...

Morgan Stanley has upgraded Sanofi ( NASDAQ: SNY) to overweight from equalweight as a recent phase 3 data release for ...

LONDON (Reuters) -Shares in French drugmaker Sanofi fell more than 9% on Thursday after late-stage trial data for its ...

Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to ...

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to ...

DISCOVER study (clinical study identifier: NCT05590585): an analysis evaluating the impact of Dupixent on skin structure in individuals with skin of colour, including lesions and epidermal thickness, ...

The anti-inflammatory medication dupilumab, marketed as Dupixent, is the subject of a lawsuit alleging a link between the use ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...